Drug Profile
MNPR 101
Alternative Names: ATN-658; huATN-658; HuATN-658 - Monopar Therapeutics; Humanised ATN-658; MNPR-101Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Attenuon LLC
- Developer Monopar Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in USA (Intraperitoneal)
- 10 Aug 2023 Monopar Therapeutics plans a first-in-human (FIH) study potentially as early as the end of this year
- 08 Mar 2022 MNPR 101 is still in preclinical development for Cancer in USA (Intraperitoneal)